LFB’s Recombinant Anti-CD20 Monoclonal Antibody Is Granted Orphan Drug Status In Europe For Chronic Lymphocytic Leukemia

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th. Chronic Lymphocytic Leukemia represents 30% of cases of leukemia in adults in Europe.

View original post here: 
LFB’s Recombinant Anti-CD20 Monoclonal Antibody Is Granted Orphan Drug Status In Europe For Chronic Lymphocytic Leukemia

Related posts:

1. Apogenix Receives Orphan Drug Designation For APG101 In The US And Positive Opinion On Orphan Product Designation In Europe Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, announced that the European Medicines Agency adopted a positive opinion on orphan medicinal product designation for the...
2. ABRAXANE(R) Receives Orphan Drug Status For The Treatment Of Pancreatic Cancer And Stage IIB-IV Melanoma Abraxis BioScience, Inc. ...
3. Memgen’s Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st...
4. Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. ...
5. Advanced Leukemia Successfully Treated With First Use Of Antibody And Stem Cell Transplantation For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell...
6. Ikano Therapeutics Receives Orphan Drug Designation For Epilepsy Drug Ikano Therapeutics, Inc. (ITI) announced that it has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively,...
7. FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer Cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and...
8. Crystal Structure Of Anti-Cancer Drug Shows How Drug Disables Harmful Copper In Cells The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain...
9. Celldex Therapeutics Presents Positive Results From Phase 2 Study Of The Antibody-Drug Conjugate Product Candidate CDX-011 In Advanced Breast Cancer Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers. As...
10. Study Could Point The Way To Drugs For Deadly Childhood Leukemia A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL). The study will help researchers...
11. New Drug Application Submitted To FDA For Tapentadol Extended Release Tablets For Management Of Chronic Pain Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release...
12. Scott And White Healthcare Researcher Finds Success With New Anti-Cancer Drug A study conducted at Scott and White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice. This drug is unique in that...
13. Anti-Cancer, Anti-Inflammatory Properties Discovered In Soy Peptide Lunasin Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia...
14. New CLINITEK(R) Status Urine Analyzers Offer Innovative Quality Checks And Connectivity Siemens expands its point-of-care urinalysis portfolio with two new systems-the CLINITEK Status®+ Analyzer, featuring several new automated quality checks (Auto-Checks) when used with Siemens urinalysis strips, and the CLINITEK Status®...
15. Arno Therapeutics Announces Poster Presentation At ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity Of AR-42 Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the...

« CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Soft Tissue Sarcomas Hypertension in Pregnancy Treatment »